List of Mozobil drug patents

Mozobil is owned by Genzyme.

Mozobil contains Plerixafor.

Mozobil has a total of 2 drug patents out of which 0 drug patents have expired.

Mozobil was authorised for market use on 15 December, 2008.

Mozobil is available in solution;subcutaneous dosage forms.

Mozobil can be used as use in combination with granulocyte-colony stimulating factor (g-csf) to mobilize hematopoietic stem cells to peripheral blood for collection & subsequent autologous transplantation in patients with non-hodgkin's lymphoma & multiple myeloma.

The generics of Mozobil are possible to be released after 22 July, 2023.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7897590 GENZYME Methods to mobilize progenitor/stem cells
Jul, 2023

(5 months from now)

US6987102 GENZYME Methods to mobilize progenitor/stem cells
Jul, 2023

(5 months from now)

Drugs and Companies using PLERIXAFOR ingredient

Market Authorisation Date: 15 December, 2008

Treatment: Use in combination with granulocyte-colony stimulating factor (g-csf) to mobilize hematopoietic stem cells to peripheral blood for collection & subsequent autologous transplantation in patients with non-hodgkin's lymphoma & multiple myeloma

Dosage: SOLUTION;SUBCUTANEOUS

How can I launch a generic of MOZOBIL before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in